Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia
This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of tocilizumab (TCZ) compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with severe COVID-19 pneumonia.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
University of California San Diego
La Jolla, California, United States
eStudySite
La Mesa, California, United States
David Geffen School of Medicine UCLA
Los Angeles, California, United States
Stanford University
Stanford, California, United States
Denver Health Medical Center
Denver, Colorado, United States
University of Miami Miller School of Medicine
Miami, Florida, United States
Rush University Medical Center
Chicago, Illinois, United States
University of Chicago
Chicago, Illinois, United States
Ochsner Clinic Foundation
Baton Rouge, Louisiana, United States
Baystate Health System
Springfield, Massachusetts, United States
Start Date
April 3, 2020
Primary Completion Date
June 24, 2020
Completion Date
July 28, 2020
Last Updated
June 30, 2021
452
ACTUAL participants
Tocilizumab (TCZ)
DRUG
Placebo
DRUG
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04466098